Capital Markets Crystal Ball: Strategies for Equity Financing

10:00 AM - 10:55 AM (PDT), Tuesday, June 9, 2020
Search General Info
Search Education
Search Partnering Companies
Access to capital is the lifeblood of biotech drug development. There are a number of avenues for raising capital, each with its own set of pros and cons, and various options seemingly falling in and out of favor as the market waxes and wanes. Gain perspective on navigating these options from some of the largest fundraisers of the past year, listen to their strategies and lessons learned from financing their drug development endeavors, and hear their predictions for what the markets may bring in the year ahead. The audience will be able to make their predictions and compare with our esteemed panelists.

Please note this session was pre-recorded but make sure to engage in the live Q & A chat.
BIO’s President & CEO, Dr. Michelle McMurry-Heath will hold a moment of silence for George Floyd during the plenary session at 11:00 am PDT.
Moderator
photo
Senior Managing Director
Evercore
Speakers
photo
Chief Financial Officer
ORIC Pharma
photo
Managing Partner
venBio
photo
Chief Financial Officer
BridgeBio
photo
Chief Financial Officer
Akero Therapeutics
photo
Senior Managing Director
Evercore